Advertisement

A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women a comparative study with vitamin D3 and estrogen–progestin therapy

      Abstract

      Objectives: To investigate the effect of vitamin K2 treatment for a year on spinal bone mineral density (BMD) in postmenopausal women, comparing with vitamin D3 hormone replacement therapy and to determine the factors which affect the efficacy of vitamin K2 therapy. Subjects and methods: Seventy-two postmenopausal women were randomized into four groups and treated with respective agents. Before the therapy, 6 and 12 months after the treatment, their lumbar spine BMD were measured by dual energy X-ray absorptiometry. The rates of change in BMD (ΔBMD) were calculated. Correlations of BMD with age, year since menopause and the initial BMD were determined. Results: Vitamin K2 suppressed the decrease in spinal BMD as compared with no treatment group. BMD in women treated with vitamin K2 was inversely correlated with their age (r=−0.54; P<0.05). Conclusions: Vitamin K2 therapy may be a useful method for preventing postmenopausal spinal bone mineral loss. In addition, the therapy should be started early in postmenopausal period.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bouckaert J.T.
        • Said A.T.
        Fracture healing by vitamin K.
        Nature. 1960; 185: 849
        • Hall J.A.G.
        • Pauli R.M.
        • Wilson K.M.
        Maternal and fetal sequelae of anticoagulation during pregnancy.
        Am. J. Med. 1980; 68: 122-140
        • Hart J.P.
        • Shearer M.J.
        • Klenerman L.
        • et al.
        Electrochemical detection of depressed circulating levels of vitamin K1 in osteoporosis.
        J. Clin. Endocrinol. Metab. 1985; 60: 1268-1269
        • Orimo H.
        • Fujita T.
        • Onomura T.
        • Inoue T.
        • Kushida K.
        • Shiraki M.
        Clinical evaluation of Ea-0167 (menatetrenone) in the treatment of osteoporosis: Phase III. Double-blind multicenter comparative with alfacalcidol (in Japanese).
        Rinshohyoka (Clin. Eval.). 1992; 20: 45-100
        • Christiansen C.
        • Christiansen M.S.
        Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.
        Lancet. 1981; 1: 459
        • Koshihara Y.
        • Hoshi K.
        • Shiraki M.
        Enhancement of mineralization of human osteoblasts by vitamin K2 (menaquinone 4) (in Japanese).
        Igaku no Ayumi (J. Clin. Exp. Med). 1992; 161: 439-440
        • Hauschka P.V.
        • Reid M.L.
        Vitamin K dependence of a calcium-binding protein containing γ-carboxyglutamic acid in chicken bone.
        J. Biol. Chem. 1978; 253: 9063-9068
        • Koshihara Y.
        • Hoshi K.
        • Shiraki M.
        Vitamin K2 (menatetrenone) inhibitsprostaglandin synthesis in cultured human osteoblast-like periosteal cells by inhibiting prostaglandin H synthase activity.
        Biochem. Pharmacol. 1993; 46: 1355-1362
        • Hara K.
        • Akiyama Y.
        • Tajima T.
        • Shiraki M.
        Menatetrenone inhibits bone resorption partly through inhibition og PGE2 synthesis in vitro.
        J. Bone Miner. Res. 1993; 8: 535-542
        • Akiyama Y.
        • Hara K.
        • Tajima T.
        • Murota S.
        • Morita I.
        Effect of vitamin K2 (menatetrenone) on osteoclast-like cell formation in mouse bone marrow cultures.
        Eur. J. Pharmacol. 1994; 263: 181-185
        • Hara K.
        • Akiyama Y.
        • Ohkawa I.
        • Tajima T.
        Effects of menatetrenone on prenisolone-induced bone loss in rats.
        Bone. 1993; 14: 813-818
        • Akiyama Y.
        • Hara K.
        • Ohkawa I.
        • Tajima T.
        Effects of menatetrenone on bone loss induced by ovariectomy in rats.
        Jpn. J. Pharmacol. 1993; 62: 145-153
        • Nagasawa Y.
        • Fujii M.
        • Kajimoto Y.
        • Imai E.
        • Hori M.
        Vitamin K2 and serum cholesterol in patients on continuous ambulatory peritoneal dialysis.
        Lancet. 1998; 351: 724